SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou H, Chen X, Wu Y
Theranostics. 2022 Jun 27;12(11):5034-5050. doi: 10.7150/thno.75121. eCollection 2022. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.